Upcoming Event: Pharma China Annual Forum 2017 in Shanghai on April 14
2/28/2017
Event: Pharma China Annual Forum
2017
Organizer: Pharma China
Sponsor(s): RDPAC, Kantar Health, Others TBA
Date: 9 AM to 5:15 PM, April 14, 2017
Venue: Le Royal Meridien Shanghai, China
Weblink: http://www.pharmachinatraining.com/coursedetail8.html
Event brochure:
PCAF 2017 Brochure+Registration+Sponsorship.pdf
Fees: CNY 6,000 ($900) for Pharma China subscribers and employees
of RDPAC member companies. CNY 6,500 ($980) for others (credit card acceptable
at 3% charge for US$ payments)
Bonus: All
participants will receive a free copy of Pharma China Annual Review and Outlook
2016/2017, as well as the latest issue of Pharma China Journal Edition.
Contact: Jenny Wang or David Xue
Tel: +86 10 84476010
Cell: +86 18601267831
Fax: +86 10 84476110
Email: jenny.wang@pharmachinaonline.com and
dxue@pharmaguys.com
Event Highlights
-
Contemporary trends & issues in Chinese Pharma in 2016 and early 2017
- Business, healthcare reform and regulatory outlook for 2017 and beyond
- Changing dynamics in Chinese pharma/healthcare landscape
- Evolving new business model and pharma sales & marketing strategies
- Trends and strategies for market access, drug R&D, partnership and
licensing
- Interactive discussion and brainstorming with our panel of top experts
Introduction
Each
year there are more uncertainties surrounding China healthcare and 2017 is no
exception. The pharmaceutical industry in China is facing an overhaul of its
business model, fast changing marketplace and repeated assaults of its
bottomlines.
The
Chinese pharmaceutical industry revenue and profit growth rebounded slightly in
2016 to 10.3% and 15.6% respectively in 2016 despite shadows of numerous
challenges stemmed from the troubled Chinese economy, regulatory shakeups, cost
containment measures and healthcare reform turbulences, according to CPIIC. On
the other hand, SMEI suggests the Chinese pharmaceutical market rose slower in
2016 at only 8.76%, compared with 11.0% in 2015. Albeit the seemingly better
industry performance, which may simply mean higher inventory in the face of
slower market growth, the era of single-digit Chinese pharmaceutical market
growth has finally arrived.
The
pharma e-commerce segment has been brewing major revolutionary developments.
Despite temporary setbacks for official liberalization of online prescription
drug sales in 2016, its prospects are sharply uplifted by government withdrawal
of approval requirements for pharma B2B and B2C businesses in early 2017. By
now, most leading players are well-positioned to take advantage of potential
opportunities.
In
the meantime, the CFDA’s move to elevate drug quality and reform drug approval
system, though contradicted by other government agency’s preoccupation to slash
drug costs, has advanced substantially in the past year. The real questions are
that, with the world’s largest population, what kind of healthcare solution and
product mix China can and should get for merely 5%-6% of GDP? Is the country
willing or able to pay more for better drugs and healthcare being pushed?
On
the front of drug pricing, the NDRC returned to the drug pricing theme in 2016
under a different flag of antitrust enforcements. By late 2016, the MOHRSS also
finalized its draft policy for proposed uniform BMI payment standards and
initiated the process to revise the National Drug Reimbursement List.
Despite
superficial slogans and touted ambitions of the Chinese government, the
healthcare reform has been hijacked by cost containment and gone astray from
the pledged path of improving efficiency and fixing structural flaws.
With
tax and other revenues drying up and under increasing threat of BMI system
deficit amid a slowing Chinese economy, local governments are pressured by both
the central government and the public to do more for healthcare with less
financial resources.
Pushed
to the corner, the Chinese pharmaceutical industry is now at the brink of
business bottomlines. Under pressures of escalating anti-corruption campaigns,
increasingly sophisticated cost containment measures as well as policy shifts
in drug pricing and reimbursements, both domestic and multinational drug
companies had no choice but to recalibrate their strategies and business models
in order to meet the challenges of the Chinese healthcare business today.
Nonetheless,
many drug company executives are still bullish about China's long-term growth
prospects. As the government improves access to healthcare, the country’s pharmaceutical
market is projected by IMS to reach approximately between $140 billion and $170
billion by 2021 on slower annual growth between 5% and 8%. But the short-term
picture is proving difficult, with reforms in the hospital sector affecting
physician prescriptions and price pressures growing for most drugs.
The
Chinese economy and the reform of its healthcare system are once again at
crossroads. Pharma companies, local or foreign, must change to remain
competitive and fit with the market.
The
Pharma China Annual Forum 2017 is an English language annual pharma industry
event oriented for foreign drug companies in China. It is sponsored by RDPAC
and WiCON International Group LLC, the publisher of WiCON|Pharma China. The
event’s emphasis is on healthcare policies, drug regulations, market access and
strategic issues as well as potential impacts of latest and upcoming policy
changes on the Chinese pharma industry. In addition, contemporary trends of
M&As, R&D and licensing, business hotspots and e-commerce, as well as
future market outlook will be explored and discussed.
At
least 10 leading experts will share their knowledge, insights and expertise.
The presentation will be followed by an interactive panel discussion with
speakers and other experts.
Fee (covering attendance, lunch and refreshments)
CNY 6,000 – Pharma China subscribers and employees of RDPAC member companies
CNY 6,500 – All other non-subscribers of Pharma China
Sponsorship opportunities
Please
contact us about sponsorship packages for refreshments and after-event
cocktail.
Registration
Spaces
are limited to 60 participants and priority is given to WiCON|Pharma China
subscribers. Please contact:
Jenny
Wang
Tel: +86 10 8447-6010 Fax: +86 10 8447-6110
Email: jenny.wang@pharmachinaonline.com or jwang.wicon@gmail.com
David
Xue
Tel: +86 10 8530-0937 Cell: +86 18601267831
Email: dxue@pharmaguys.com